EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Prophylactic Enoxaparin Anti-Xa Levels in Individuals ≥150 kg

Logan M Olson, Shelby R Wells, William J Peppard, Bradley J Peters, Elizabeth R Lyden, Emily F Cantrell

Thrombosis and Haemostasis · 28.01.2026

DOI: 10.1055/a-2791-6535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 28.01.2026. Verfasst von Logan M Olson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nebraska Medicine, Omaha, Nebraska, United States. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimal dosing of prophylactic enoxaparin for individuals ≥150 kg is unknown due to limited inclusion in previous studies. Estimate an optimal weight-based prophylactic enoxaparin dose for individuals ≥150 kg. This multicenter, retrospective study included ≥150 kg adult patients admitted to the hospital between January 2014 and April 2024, who received twice daily prophylactic enoxaparin (goal peak anti-Xa 0.2–0.4 IU/mL). At least one peak anti-Xa was required, obtained 3 to 5 hours after the 3rd consecutive dose. The primary outcome was the range of dosing that produced goal prophylactic peak anti-Xa following linear regression modeling. Secondary outcomes were hospital and intensive care unit (ICU)/progressive care unit (PCU) length of stay (LOS), in-hospital mortality, and VTE/bleed events within 72 hours after an eligible peak anti-Xa. A total of 311 encounters and 388 peak anti-Xa levels were assessed. Patients were 46 (37–55) years old, 53.1% were male, and weighed 183.3 kg (166.1–204.1) with a BMI of 61.3 kg/m2 (54.8–69.4). Creatinine clearance was 179.6 mL/min (126.5–228.2) and patients received 4 doses (4–6) before peak anti-Xa, with a time between of 249 minutes (227–271). Linear regression modeling revealed a statistically significant correlation (r2 = 0.27) between weight-based dose and peak anti-Xa (p < 0.0001). Enoxaparin 0.34 mg/kg (95% CI 0.33–0.36) twice daily was predicted to achieve a peak anti-Xa of 0.3 IU/mL. Hospital LOS was 8 days (4–15), ICU/PCU LOS was 8 days (4–14, n = 158), and only two patients (0.6%) died during hospitalization. One VTE event was observed. Our results suggest an appropriate empiric weight-based prophylactic enoxaparin dose for hospitalized patients ≥150 kg is 0.34 mg/kg twice daily.

Autor:innen und Institutionen

  • Department of Pharmacy, Nebraska Medicine, Omaha, Nebraska, United States.
  • Department of Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
  • Department of Pharmacy, Mayo Clinic Rochester, Rochester, Minnesota, United States.
  • Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska, United States.
  • Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, United States.

Zitieren

APA

Olson, L. M., Wells, S. R., Peppard, W. J., Peters, B. J., Lyden, E. R., & Cantrell, E. F. (2026). Evaluation of Prophylactic Enoxaparin Anti-Xa Levels in Individuals ≥150 kg. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2791-6535

Vancouver

Olson LM, Wells SR, Peppard WJ, Peters BJ, Lyden ER, Cantrell EF. Evaluation of Prophylactic Enoxaparin Anti-Xa Levels in Individuals ≥150 kg. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2791-6535

BibTeX
@article{Olson2026,
  author = {Olson, Logan M and Wells, Shelby R and Peppard, William J and Peters, Bradley J and Lyden, Elizabeth R and Cantrell, Emily F},
  title = {Evaluation of Prophylactic Enoxaparin Anti-Xa Levels in Individuals ≥150 kg},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1055/a-2791-6535}
}
Kostenlos starten →